See more : Supra Pacific Financial Servic (SUPRAPFSL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Biomerica, Inc. (BMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biomerica, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Revelstone Capital Acquisition Corp. (RCACW) Income Statement Analysis – Financial Results
- Yamabiko Corporation (6250.T) Income Statement Analysis – Financial Results
- Zicom Group Limited (ZGL.AX) Income Statement Analysis – Financial Results
- Acconeer AB (publ) (ACCON.ST) Income Statement Analysis – Financial Results
- First Responder Technologies Inc. (WPNNF) Income Statement Analysis – Financial Results
Biomerica, Inc. (BMRA)
About Biomerica, Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.42M | 5.34M | 18.87M | 7.20M | 6.69M | 5.20M | 5.56M | 5.79M | 5.14M | 4.96M | 5.12M | 6.47M | 6.08M | 4.90M | 5.08M | 4.93M | 4.93M | 5.75M | 7.18M | 9.27M | 9.17M | 9.06M | 8.60M | 8.94M | 8.03M | 8.70M | 9.40M | 9.20M | 9.50M | 9.20M | 8.30M | 8.00M | 7.80M | 10.40M | 8.20M | 1.20M | 1.40M | 1.90M | 1.70M |
| Cost of Revenue | 4.80M | 4.89M | 15.89M | 6.70M | 4.91M | 3.91M | 3.81M | 3.77M | 3.62M | 3.42M | 3.45M | 4.05M | 3.78M | 3.37M | 3.51M | 2.96M | 2.79M | 3.50M | 4.78M | 6.19M | 6.25M | 6.16M | 6.06M | 6.13M | 5.40M | 5.10M | 5.30M | 5.20M | 5.10M | 4.80M | 4.30M | 4.80M | 4.80M | 6.70M | 4.00M | 800.00K | 1.00M | 800.00K | 1.20M |
| Gross Profit | 611.00K | 446.00K | 2.98M | 496.98K | 1.78M | 1.29M | 1.75M | 2.02M | 1.52M | 1.54M | 1.67M | 2.43M | 2.30M | 1.53M | 1.56M | 1.97M | 2.14M | 2.25M | 2.41M | 3.09M | 2.92M | 2.90M | 2.54M | 2.81M | 2.63M | 3.60M | 4.10M | 4.00M | 4.40M | 4.40M | 4.00M | 3.20M | 3.00M | 3.70M | 4.20M | 400.00K | 400.00K | 1.10M | 500.00K |
| Gross Profit Ratio | 11.28% | 8.35% | 15.78% | 6.90% | 26.62% | 24.84% | 31.53% | 34.91% | 29.65% | 31.07% | 32.60% | 37.51% | 37.78% | 31.14% | 30.75% | 39.92% | 43.35% | 39.07% | 33.48% | 33.27% | 31.81% | 31.99% | 29.49% | 31.43% | 32.75% | 41.38% | 43.62% | 43.48% | 46.32% | 47.83% | 48.19% | 40.00% | 38.46% | 35.58% | 51.22% | 33.33% | 28.57% | 57.89% | 29.41% |
| Research & Development | 1.49M | 1.58M | 1.81M | 2.41M | 1.91M | 1.68M | 1.40M | 1.13M | 780.33K | 733.64K | 589.87K | 459.09K | 347.13K | 420.57K | 455.17K | 278.31K | 259.09K | 256.10K | 239.00K | 274.29K | 273.98K | 262.84K | 159.76K | 322.12K | 898.12K | 500.00K | 600.00K | 300.00K | 300.00K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.61K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.49M | 6.09M | 5.70M | 4.61M | 2.27M | 2.03M | 1.84M | 1.85M | 1.57M | 1.48M | 1.53M | 1.45M | 1.45M | 1.24M | 1.47M | 1.44M | 1.37M | 1.47M | 2.26M | 3.05M | 2.96M | 2.85M | 2.84M | 3.17M | 5.70M | 3.10M | 3.10M | 2.90M | 3.10M | 3.30M | 3.40M | 3.00M | 3.60M | 4.80M | 3.70M | 1.20M | 1.90M | 2.30M | 2.40M |
| Other Expenses | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.01K | 2.26K | 3.13K | 50.00 | 0.00 | 290.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.98M | 7.67M | 7.51M | 7.02M | 4.18M | 3.70M | 3.24M | 2.98M | 2.35M | 2.21M | 2.12M | 1.91M | 1.79M | 1.66M | 1.93M | 1.72M | 1.63M | 1.72M | 2.50M | 3.32M | 3.23M | 3.11M | 3.00M | 3.49M | 6.82M | 3.90M | 3.90M | 3.40M | 3.70M | 4.00M | 3.80M | 3.50M | 4.40M | 5.60M | 4.20M | 1.30M | 2.00M | 2.40M | 2.60M |
| Cost & Expenses | 11.78M | 12.56M | 23.41M | 13.72M | 9.10M | 7.61M | 7.05M | 6.75M | 5.97M | 5.63M | 5.57M | 5.96M | 5.58M | 5.03M | 5.44M | 4.69M | 4.42M | 5.23M | 7.28M | 9.51M | 9.48M | 9.27M | 9.06M | 9.62M | 12.22M | 9.00M | 9.20M | 8.60M | 8.80M | 8.80M | 8.10M | 8.30M | 9.20M | 12.30M | 8.20M | 2.10M | 3.00M | 3.20M | 3.80M |
| Interest Income | 431.00K | 133.00K | 26.64K | 66.86K | 71.19K | 44.01K | 47.76K | 46.35K | 24.12K | 21.91K | 17.18K | 10.71K | 8.35K | 7.37K | 14.71K | 29.87K | 33.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 26.64K | 367.00 | 9.00 | 47.00 | 37.00 | 282.00 | 167.00 | 0.00 | 142.00 | 302.00 | 1.59K | 5.83K | 12.32K | 27.52K | 49.54K | 35.05K | 0.00 | 0.00 | 0.00 | 0.00 | 40.37K | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 374.00K | 351.00K | 594.82K | 375.86K | 398.63K | 162.91K | 186.60K | 219.22K | 232.42K | 253.28K | 207.03K | 216.71K | 180.12K | 147.81K | 114.01K | 88.65K | 65.83K | 56.74K | 122.05K | 159.32K | 144.16K | 116.55K | 192.42K | 208.99K | 222.33K | 300.00K | 200.00K | 200.00K | 300.00K | 400.00K | 400.00K | 500.00K | 800.00K | 800.00K | 500.00K | 100.00K | 100.00K | 100.00K | 200.00K |
| EBITDA | -5.99M | -6.74M | -3.94M | -7.06M | -2.27M | -2.21M | -1.25M | -689.34K | -563.57K | -393.15K | -219.25K | 741.48K | 795.16K | 313.09K | -218.12K | 383.36K | 1.72M | 537.49K | 24.96K | -75.45K | -171.98K | -93.34K | -273.00K | -408.86K | -3.97M | 0.00 | 400.00K | 800.00K | 1.00M | 800.00K | 600.00K | 200.00K | -600.00K | -1.10M | 800.00K | -800.00K | -1.50M | -1.20M | -1.90M |
| EBITDA Ratio | -110.67% | -128.71% | -20.73% | -84.45% | -28.88% | -42.42% | -22.42% | -11.90% | -10.96% | -7.92% | -4.28% | 11.45% | 11.27% | 6.39% | -4.65% | 7.42% | -11.66% | 9.35% | -0.29% | -1.20% | -2.74% | -1.80% | -2.80% | -5.84% | -50.86% | -3.45% | 2.13% | 7.61% | 10.53% | 8.70% | 7.23% | 1.25% | -8.97% | -10.58% | 9.76% | -75.00% | -178.57% | -57.89% | -105.88% |
| Operating Income | -6.37M | -7.22M | -4.53M | -6.52M | -2.40M | -2.41M | -1.48M | -954.63K | -826.95K | -670.60K | -446.59K | 514.01K | 505.00K | -132.26K | -364.52K | 247.66K | 509.49K | 520.79K | -97.09K | -234.76K | -316.14K | -209.88K | -465.42K | -683.58K | -4.19M | -300.00K | 200.00K | 600.00K | 700.00K | 400.00K | 200.00K | -300.00K | -1.40M | -1.90M | 300.00K | -900.00K | -1.60M | -1.30M | -2.10M |
| Operating Income Ratio | -117.58% | -135.29% | -24.03% | -90.60% | -35.90% | -46.39% | -26.63% | -16.48% | -16.09% | -13.51% | -8.72% | 7.94% | 8.30% | -2.70% | -7.18% | 5.02% | 10.34% | 9.06% | -1.35% | -2.53% | -3.45% | -2.32% | -5.41% | -7.65% | -52.16% | -3.45% | 2.13% | 6.52% | 7.37% | 4.35% | 2.41% | -3.75% | -17.95% | -18.27% | 3.66% | -75.00% | -114.29% | -68.42% | -123.53% |
| Total Other Income/Expenses | 431.00K | 134.00K | 26.64K | 66.50K | 71.18K | 43.97K | 47.73K | 46.07K | 30.97K | 24.16K | 20.17K | 10.46K | 108.45K | 291.71K | 20.07K | 19.52K | 1.13M | 4.99K | 785.00 | 215.24K | 18.91K | -11.77K | -99.19K | 103.21K | 301.56K | 300.00K | -200.00K | 100.00K | 0.00 | 0.00 | 100.00K | 100.00K | 100.00K | 900.00K | -300.00K | 100.00K | 1.00M | -100.00K | -100.00K |
| Income Before Tax | -5.94M | -7.09M | -4.51M | -6.46M | -2.33M | -2.37M | -1.43M | -908.56K | -795.99K | -646.43K | -426.42K | 524.46K | 613.45K | 159.45K | -344.46K | 267.18K | 1.64M | 525.78K | 155.37K | -19.53K | -297.23K | -221.65K | -564.61K | -576.49K | -3.89M | 0.00 | 400.00K | 700.00K | 0.00 | 0.00 | 300.00K | -200.00K | -1.30M | -1.00M | 0.00 | -800.00K | -600.00K | -1.40M | -2.20M |
| Income Before Tax Ratio | -109.62% | -132.78% | -23.88% | -89.68% | -34.84% | -45.55% | -25.77% | -15.69% | -15.49% | -13.03% | -8.33% | 8.10% | 10.09% | 3.25% | -6.79% | 5.41% | 33.35% | 9.15% | 2.16% | -0.21% | -3.24% | -2.45% | -6.57% | -6.45% | -48.40% | 0.00% | 4.26% | 7.61% | 0.00% | 0.00% | 3.61% | -2.50% | -16.67% | -9.62% | 0.00% | -66.67% | -42.86% | -73.68% | -129.41% |
| Income Tax Expense | 42.00K | 51.00K | 23.72K | 13.06K | 7.39K | 24.24K | 31.80K | 46.64K | 703.80K | -315.02K | -210.76K | -12.49K | 65.01K | 2.00K | -13.00K | -87.00K | -67.00K | 16.77K | 1.60K | 1.94K | 1.82K | 2.22K | 2.06K | 2.40K | 2.40K | -200.00K | 100.00K | 200.00K | 300.00K | 300.00K | 300.00K | 100.00K | -500.00K | 200.00K | 600.00K | 0.00 | -1.20M | 0.00 | -200.00K |
| Net Income | -5.98M | -7.14M | -4.53M | -6.47M | -2.34M | -2.39M | -1.47M | -908.56K | -1.50M | -331.41K | -215.66K | 536.96K | 548.44K | 157.45K | -331.46K | 354.18K | 1.71M | 536.88K | 230.27K | 162.26K | -223.20K | -223.87K | -420.74K | -2.67M | -3.89M | -100.00K | 100.00K | 400.00K | 400.00K | 100.00K | 0.00 | -400.00K | -900.00K | -1.20M | -600.00K | -900.00K | -400.00K | -1.30M | -1.90M |
| Net Income Ratio | -110.40% | -133.73% | -24.01% | -89.86% | -34.95% | -46.01% | -26.34% | -15.69% | -29.18% | -6.68% | -4.21% | 8.30% | 9.02% | 3.21% | -6.53% | 7.18% | 34.71% | 9.34% | 3.20% | 1.75% | -2.43% | -2.47% | -4.89% | -29.89% | -48.43% | -1.15% | 1.06% | 4.35% | 4.21% | 1.09% | 0.00% | -5.00% | -11.54% | -11.54% | -7.32% | -75.00% | -28.57% | -68.42% | -111.76% |
| EPS | -0.36 | -0.50 | -0.36 | -0.54 | -0.23 | -0.26 | -0.17 | -0.11 | -0.20 | -0.04 | -0.03 | 0.08 | 0.08 | 0.02 | -0.05 | 0.05 | 0.28 | 0.09 | 0.04 | 0.03 | -0.04 | -0.04 | -0.08 | -0.56 | -0.86 | -0.03 | 0.04 | 0.12 | 0.12 | 0.03 | 0.02 | -0.14 | -0.30 | -0.40 | -0.18 | -0.30 | -0.14 | -0.44 | -0.66 |
| EPS Diluted | -0.36 | -0.50 | -0.36 | -0.54 | -0.23 | -0.26 | -0.17 | -0.11 | -0.20 | -0.04 | -0.03 | 0.07 | 0.08 | 0.02 | -0.05 | 0.05 | 0.25 | 0.08 | 0.03 | 0.03 | -0.04 | -0.04 | -0.08 | -0.56 | -0.86 | -0.03 | 0.03 | 0.10 | 0.12 | 0.03 | 0.02 | -0.14 | -0.30 | -0.40 | -0.18 | -0.30 | -0.14 | -0.44 | -0.66 |
| Weighted Avg Shares Out | 16.82M | 14.15M | 12.67M | 11.93M | 10.17M | 9.21M | 8.57M | 8.26M | 7.50M | 7.55M | 7.19M | 7.02M | 6.89M | 6.67M | 6.65M | 6.62M | 6.13M | 5.93M | 5.76M | 5.75M | 5.74M | 5.30M | 5.10M | 4.81M | 4.54M | 4.00M | 4.00M | 3.86M | 3.59M | 3.33M | 3.33M | 2.86M | 3.00M | 3.00M | 3.33M | 3.00M | 2.86M | 2.95M | 2.88M |
| Weighted Avg Shares Out (Dil) | 16.82M | 14.15M | 12.67M | 11.93M | 10.17M | 9.21M | 8.57M | 8.33M | 7.63M | 7.55M | 7.37M | 7.45M | 7.11M | 6.70M | 6.65M | 7.01M | 6.98M | 6.51M | 6.22M | 6.62M | 5.74M | 5.30M | 5.10M | 4.81M | 4.54M | 4.00M | 4.00M | 3.87M | 3.59M | 3.33M | 3.33M | 2.86M | 3.00M | 3.00M | 3.33M | 3.00M | 2.86M | 2.95M | 2.88M |
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn's Disease, and Ulcerative Colitis
IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease (“GERD”), Crohn's Disease, and...
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements
IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet...
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, is excited to announce a major enhancement to its inFoods® IBS platform. US consumers can now seamlessly order the inFoods®...
Biomerica Reports First Quarter Fiscal 2025 Financial Results
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2025 ended August 31, 2024.
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica,...
Biomerica Reports Fiscal 2024 Year End Results
IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company achieved a modest increase in net sales to $5.4 million, compared to $5.3...
Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers
IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience.
Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024
IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products, today announced the initiation of a pilot program for its inFoods® IBS product with a large...
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
IRVINE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Biomerica Inc. (Nasdaq: BMRA), is proud to announce a multi-year exclusive distribution agreement with one of the UAE's most substantial healthcare conglomerates. This strategic alliance is set to revolutionize the accessibility and...
Biomerica provides update on inFoods® IBS expansion
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas.
Source: https://incomestatements.info
Category: Stock Reports